PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Borsa Italiana 20:05:32 02/07/2024 BST | ||
| 1.279 EUR | +24.54% |
|
| Current month | +5.38% | ||
| 1 month | -39.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 02/07/24 | 1.279 | +24.54% |
| 01/07/24 | 1.027 | -13.70% |
| 28/06/24 | 1.19 | +9.48% |
| 27/06/24 | 1.087 | +1.87% |
| 26/06/24 | 1.067 | +27.78% |
Real-time Borsa Italiana
Last update July 02, 2024 at 08:05 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| F45210 | |
| ISIN | DE000VD048J1 |
| Date issued | 06/03/2024 |
| Strike | 1,076 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.84 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.36 € |
|---|---|
| Lowest since issue | 0.635 € |
| Spread | 0.134 € |
| Spread % | 10.10% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,005
DKK
Average target price
952.2
DKK
Spread / Average Target
-5.22%
- Stock Market
- Certificates
- F45210 Certificat
